









Markets
/
Stocks
/
nasdaq-phvs
/

Pharvaris NV

PHVS

21.780USD

+0.820+3.91%

Close 10/15, 16:00（ET）Quotes delayed by 15 min

1.19BMarket Cap

LossP/E TTM



Pharvaris NV

21.780

+0.820+3.91%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pharvaris NV

Currency: USD Updated: 2025-10-14

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pharvaris NV's Score

Industry at a Glance

Industry Ranking

235 / 501

Overall Ranking

403 / 4694

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

34.455

Target Price

+56.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pharvaris NV Highlights

StrengthsRisks

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -8.96, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.75M shares, decreasing 3.62% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 3.65M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-14

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Pharvaris NV's Company Valuation

Currency: USD Updated: 2025-10-14

The company’s current valuation score is 6.58, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -8.96, which is -66.70% below the recent high of -2.99 and -50.26% above the recent low of -13.47.

Score

Industry at a Glance

Previous score

6.58

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 235/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-14

The company’s current earnings forecast score is 8.73, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Pharvaris NV is 32.00, with a high of 52.00 and a low of 27.00.

Score

Industry at a Glance

Previous score

8.73

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

36.583

Target Price

+74.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

514

Total

Median

Average

Company name

Ratings

Analysts

Pharvaris NV

PHVS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

103

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-14

The company’s current price momentum score is 6.63, which is lower than the Biotechnology & Medical Research industry's average of 6.87. Sideways: Currently, the stock price is trading between the resistance level at 24.33 and the support level at 19.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.71

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.680

Sell

RSI(14)

41.728

Neutral

STOCH(KDJ)(9,3,3)

21.619

Neutral

ATR(14)

1.386

High Vlolatility

CCI(14)

-101.035

Sell

Williams %R

77.801

Sell

TRIX(12,20)

-0.209

Sell

StochRSI(14)

64.637

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

21.926

Sell

MA10

22.487

Sell

MA20

23.555

Sell

MA50

22.973

Sell

MA100

20.923

Buy

MA200

18.685

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-14

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 76.10%, representing a quarter-over-quarter decrease of 6.63%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 3.65M shares, representing 5.70% of shares outstanding, with 15.11% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

General Atlantic LLC

7.53M

Fidelity Management & Research Company LLC

5.42M

+0.50%

Foresite Capital Management, LLC

4.41M

VenBio Partners LLC

4.29M

Viking Global Investors LP

Star Investors

3.65M

EQT Life Sciences

3.56M

Bain Capital Life Sciences Investors, LLC

3.30M

VR Adviser, LLC

2.05M

-34.22%

Deerfield Management Company, L.P.

2.02M

Commodore Capital LP

1.91M

Risk Assessment

Currency: USD Updated: 2025-10-14

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -2.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.